Search

Your search keyword '"Lim, Dawn"' showing total 1,604 results
Start Over Author "Lim, Dawn" Search Limiters Peer Reviewed
1,604 results on '"Lim, Dawn"'

5. Management of corneal neovascularization: Current and emerging therapeutic approaches.

Author

Duoduo Wu, Kai En Chan, Xiao Hong Lim, Blanche, Ka-Ann Lim, Dawn, Meihua Wong, Wendy, Chai, Charmaine, Manotosh, Ray, and Hong Long Lim, Chris

Subjects
LIMBAL stem cell deficiency, CORNEA, PATHOLOGIC neovascularization, CHEMICAL burns, THERAPEUTICS, NEOVASCULARIZATION
Abstract

Corneal neovascularization (CoNV) is a sight-threatening condition affecting an estimated 1.4 million people per year, and the incidence is expected to rise. It is a complication of corneal pathological diseases such as infective keratitis, chemical burn, corneal limbal stem cell deficiency, mechanical trauma, and immunological rejection after keratoplasties. CoNV occurs due to a disequilibrium in proangiogenic and antiangiogenic mediators, involving a complex system of molecular interactions. Treatment of CoNV is challenging, and no therapy thus far has been curative. Anti-inflammatory agents such as corticosteroids are the mainstay of treatment due to their accessibility and well-studied safety profile. However, they have limited effectiveness and are unable to regress more mature neovascularization. With the advent of advanced imaging modalities and an expanding understanding of its pathogenesis, contemporary treatments targeting a wide array of molecular mechanisms and surgical options are gaining traction. This review aims to summarize evidence regarding conventional and emerging therapeutic options for CoNV. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

15. Assessing utility, impact and adoption challenges of AI-enabled prescription advisory tool for type 2 diabetes management: perspectives from endocrinologists in a tertiary hospital (Preprint)

Author

Yoon, Sungwon, primary, Goh, Hendra, additional, Lee, Phong Ching, additional, Tan, Hong Chang, additional, Teh, Ming Ming, additional, Lim, Dawn Shao Ting, additional, Kwee, Ann, additional, Suresh, Chandran, additional, Carmody, David, additional, Swee, Du Soon, additional, Tan, Sarah Ying Tse, additional, Wong, Andy Jun-Wei, additional, Choo, Charlotte Hui-Min, additional, Wee, Zongwen, additional, and Bee, Yong Mong, additional

Published
2023
Full Text
View/download PDF

21. Expanding the use of salivary cortisol as a non-invasive outpatient test in the dynamic evaluation of suspected adrenal insufficiency

Author

Tan, Sarah Ying Tse, primary, Tan, Hong Chang, additional, Zhu, Ling, additional, Loh, Lih Ming, additional, Lim, Dawn Shao Ting, additional, Swee, Du Soon, additional, Chan, Yoke Ling, additional, Lim, Huee Boon, additional, Ling, Shiau Lee, additional, Ou, En Jun, additional, Teo, Wynn Ee, additional, Zhang, Xiao Ping, additional, Goh, Hui Fen, additional, and Kek, Peng Chin, additional

Published
2023
Full Text
View/download PDF

22. Impact of Microplastics on the Ocular Surface

Author

Wu, Duoduo, primary, Lim, Blanche X. H., additional, Seah, Ivan, additional, Xie, Shay, additional, Jaeger, Julia E., additional, Symons, Robert K., additional, Heffernan, Amy L., additional, Curren, Emily E. M., additional, Leong, Sandric C. Y., additional, Riau, Andri K., additional, Lim, Dawn K. A., additional, Stapleton, Fiona, additional, Ali, Mohammad Javed, additional, Singh, Swati, additional, Tong, Louis, additional, Mehta, Jodhbir S., additional, Su, Xinyi, additional, and Lim, Chris H. L., additional

Published
2023
Full Text
View/download PDF

26. The Management of Ocular Surface Squamous Neoplasia (OSSN)

Author

Yeoh, Clarice H. Y., primary, Lee, Jerome J. R., additional, Lim, Blanche X. H., additional, Sundar, Gangadhara, additional, Mehta, Jodhbir S., additional, Chan, Anita S. Y., additional, Lim, Dawn K. A., additional, Watson, Stephanie L., additional, Honavar, Santosh G., additional, Manotosh, Ray, additional, and Lim, Chris H. L., additional

Published
2022
Full Text
View/download PDF

34. Phase 3, Randomized, 20-Month Study of the Efficacy and Safety of Bimatoprost Implant in Patients with Open-Angle Glaucoma and Ocular Hypertension (ARTEMIS 2)

Author

Bacharach, Jason, Tatham, Andrew, Ferguson, Gloria, Belalcázar, Sandra, Thieme, Hagen, Goodkin, Margot L., Chen, Michelle Y., Guo, Qiang, Liu, Jeen, Robinson, Michael R., Bejanian, Marina, Wirta, David L., Alezzandrini, Arturo, Bercovich, Gabriel, Deromedis, Pablo, Furno Sola, Federico, Gentile, Carolina, Lerner, Simon, Lupinacci, Anahi, Zeolite, Carlos, Birt, Catherine, Crichton, Andrew, Gagne, Sebastien, Giunta, Michael, Harasymowycz, Paul, Jinapriya, Delan, Nicolela, Marcelo, Nixon, Donald, Saurel, Patrick, Yan, David, Yuen, Darana, Arango, Santiago, Martinez, Alexander, Parra Restrepo, Juan C., Korda, Vladimir, Kadlecova, Jana, Svacinova, Jitka, Khairy, Hany, El Ibiary, Hani, El Sanabary, Zeinab, Bell, Katharina, Greslechner, Roman, Koch, Jöerg, Lorenz, Katrin, Oberacher-Velten, Isabel, Schmickler, Stefanie, Schuart, Claudie, Bandello, Francesco, Cagini, Carlos, Figus, Michele, Mastropasqua, Leonardo, Rossetti, Luca, Uva, Maurizio G., Thayanithi, Sandragasu, Wells, Anthony, Husain, Rahat, Koh, Victor, Lim, Dawn, Tin, Aung, Gous, Petrus, Venter, Lynette, Kee, Changwon, Kook, Michael, Park, Ki-Ho, Eraslan, Muhsin, Kayikcioglu, Ozcan, Yildirim, Nilgun, Bourne, Rupert R. A., Choudhary, Anshoo, Cordeiro, Francesca, Dubois, Vincent, Kirwan, James, Lim, Sheng, Martin, Keith, Nithy, Antony, Prabhu, Avinash, Amir, Ahmad, Barnebey, Howard, Beck, Allen, Bergstrom, Lance, Borisuth, Navaneet, Branch, James D., Briggs, Jonathan, Bylsma, Stephen, Chang, Peter, Christie, William, Cotter, Frank, Depenbusch, Michael, Goldberg, Damien F., Greiner, Jack, Gupta, Shailesh, Gutmark, Ron, Han, Ying, Heersink, Sebastian, Kahook, Malik, Khouri, Albert, Kim, Joshua, Kushnick, Howard, Lin, Christopher, Luchs, Jodi, Maharaj, Arindel, Mansberger, Steven L., Mares, Frank, Miller-Ellis, Eydie, Modi, Satish, Paul, Matthew, Pitha, Ian, Saltzmann, Robert, Sato, Michelle, Savestsky, Michael, Segal, Bruce, Segal, Zachary, Serle, Janet, Sherwood, Mark, Singh, Inder, Smith, Stephen E., Song, Julia, Sorenson, Robert, Tenkman, Lawrence, Tekwani, Navin, Tubbs, Carl, Tyson, Farrell, Vizzeri, Gianmarco, Vold, Steven, Vu, Qui, Warren, Kimberly S., and Wirta, David

Subjects
genetic structures, sense organs, eye diseases
Abstract

Objective-\ud \ud To evaluate the intraocular pressure (IOP)-lowering efficacy and safety of 10 and 15 µg bimatoprost implant in patients with open-angle glaucoma (OAG) or ocular hypertension (OHT).\ud \ud Methods-\ud \ud This randomized, 20-month, multicenter, masked, parallel-group, phase 3 trial enrolled 528 patients with OAG or OHT and an open iridocorneal angle inferiorly in the study eye. Study eyes were administered 10 or 15 µg bimatoprost implant on day 1, week 16, and week 32, or twice-daily topical timolol maleate 0.5%. Primary endpoints were IOP and IOP change from baseline through week 12. Safety measures included treatment-emergent adverse events (TEAEs) and corneal endothelial cell density (CECD).\ud \ud Results-\ud \ud Both 10 and 15 µg bimatoprost implant met the primary endpoint of noninferiority to timolol in IOP lowering through 12 weeks. Mean IOP reductions from baseline ranged from 6.2–7.4, 6.5–7.8, and 6.1–6.7 mmHg through week 12 in the 10 µg implant, 15 µg implant, and timolol groups, respectively. IOP lowering was similar after the second and third implant administrations. Probabilities of requiring no IOP-lowering treatment for 1 year after the third administration were 77.5% (10 µg implant) and 79.0% (15 µg implant). The most common TEAE was conjunctival hyperemia, typically temporally associated with the administration procedure. Corneal TEAEs of interest (primarily corneal endothelial cell loss, corneal edema, and corneal touch) were more frequent with the 15 than the 10 µg implant and generally were reported after repeated administrations. Loss in mean CECD from baseline to month 20 was ~ 5% in 10 µg implant-treated eyes and ~ 1% in topical timolol-treated eyes. Visual field progression (change in the mean deviation from baseline) was reduced in the 10 µg implant group compared with the timolol group.\ud \ud Conclusions-\ud \ud The results corroborated the previous phase 3 study of the bimatoprost implant. The bimatoprost implant met the primary endpoint and effectively lowered IOP. The majority of patients required no additional treatment for 12 months after the third administration. The benefit-risk assessment favored the 10 over the 15 µg implant. Studies evaluating other administration regimens with reduced risk of corneal events are ongoing. The bimatoprost implant has the potential to improve adherence and reduce treatment burden in glaucoma.

Published
2021

35. The Management of Ocular Surface Squamous Neoplasia (OSSN).

Author

Yeoh, Clarice H. Y., Lee, Jerome J. R., Lim, Blanche X. H., Sundar, Gangadhara, Mehta, Jodhbir S., Chan, Anita S. Y., Lim, Dawn K. A., Watson, Stephanie L., Honavar, Santosh G., Manotosh, Ray, and Lim, Chris H. L.

Subjects
TUMORS, CANCER chemotherapy, MITOMYCIN C, OPHTHALMOLOGISTS
Abstract

The rise of primary topical monotherapy with chemotherapeutic drugs and immunomodulatory agents represents an increasing recognition of the medical management of ocular surface squamous neoplasia (OSSN), which may replace surgery as the standard of care in the future. Currently, there is no consensus regarding the best way to manage OSSN with no existing guidelines to date. This paper seeks to evaluate evidence surrounding available treatment modalities and proposes an approach to management. The approach will guide ophthalmologists in selecting the most appropriate treatment regime based on patient and disease factors to minimize treatment related morbidity and improve OSSN control. Further work can be done to validate this algorithm and to develop formal guidelines to direct the management of OSSN. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

37. Tolerability and Efficacy of Long-Term Medical Therapy in Primary Aldosteronism

Author

Tang, Fengjie, primary, Loh, Lih M, additional, Foo, Roger S, additional, Loh, Wann J, additional, Lim, Dawn S T, additional, Zhang, Meifen, additional, Tan, Pei T, additional, Swee, Du S, additional, Khoo, Joan, additional, Tay, Donovan, additional, Lee, Lynette, additional, Tan, Sarah Y, additional, Zhu, Ling, additional, Soh, Shui B, additional, Tan, Eberta, additional, Kek, Peng C, additional, and Puar, Troy H, additional

Published
2021
Full Text
View/download PDF

42. Neutrophil-to-Lymphocyte Ratio Predicts Development of Immune-Related Adverse Events and Outcomes from Immune Checkpoint Blockade: A Case-Control Study

Author

Lee, Pei Yi, primary, Oen, Kellynn Qi Xuan, additional, Lim, Grace Rui Si, additional, Hartono, Juanda Leo, additional, Muthiah, Mark, additional, Huang, Daniel Q., additional, Teo, Felicia Su Wei, additional, Li, Andrew Yunkai, additional, Mak, Anselm, additional, Chandran, Nisha Suyien, additional, Tan, Chris Lixian, additional, Yang, Peiling, additional, Tai, E Shyong, additional, Ng, Kay Wei Ping, additional, Vijayan, Joy, additional, Chan, Yee Cheun, additional, Tan, Li Ling, additional, Lee, Martin Beng-Huat, additional, Chua, Horng Ruey, additional, Hong, Wei Zhen, additional, Yap, Eng Soo, additional, Lim, Dawn K., additional, Yuen, Yew Sen, additional, Chan, Yiong Huak, additional, Aminkeng, Folefac, additional, Wong, Alvin Seng Cheong, additional, Huang, Yiqing, additional, and Tay, Sen Hee, additional

Published
2021
Full Text
View/download PDF

48. Blitzer Eyes Next Act After Building $35 Billion Blackstone Unit.

Author

Lim, Dawn, Tan, Gillian, and Perlberg, Heather

Subjects
CHIEF operating officers
Abstract

David Blitzer, a prominent figure at Blackstone Inc., is preparing for his next venture after leading the firm's $35 billion tactical opportunities unit. Blitzer is expected to step back from day-to-day responsibilities and transition into an advisory or chair role. Chris James, the chief operating officer of the unit, is the top contender to take over. Blitzer's scaling back reflects a trend at Blackstone, where investment decisions are increasingly driven by committee rather than individual personalities. Blitzer is also known for his sports-focused empire outside of Blackstone, which includes ownership stakes in various sports teams. [Extracted from the article]

Published
2024

49. Biden's Biggest Donors Left Powerless to Sway Him to End Bid.

Author

Gordon, Amanda, Allison, Bill, and Lim, Dawn

Subjects
DEMOCRATS (United States), CHARITABLE giving
Abstract

Wall Street's influential donors are resigned to watching and waiting as the Democratic Party faces a major crisis. While many believe that a change at the top of the ticket would boost the Democrats' chances of beating Donald Trump, there is no obvious path for these donors to make that change happen themselves. Efforts to drum up funds for an alternative candidate have fallen short, and some donors are choosing to sit on the sidelines to avoid fueling a narrative that financiers are pushing Biden out. Despite concerns about Biden's age, he remains committed to staying in the race and beating Trump. However, donations to his campaign have thinned in recent days, with some wealthy donors withholding contributions until Biden is off the ticket. Trump's campaign has caught up and surpassed Biden in fundraising, and some donors are considering diverting their money to House and Senate races instead. Some Democratic donors have launched long-shot efforts to find a replacement for Biden, but these efforts are unlikely to succeed. [Extracted from the article]

Published
2024

50. Biden's Biggest Donors Left Powerless to Sway Him to Quit Race.

Author

Gordon, Amanda, Allison, Bill, and Lim, Dawn

Subjects
DEMOCRATS (United States), RESIGNATION of employees, CHARITABLE giving
Abstract

Wall Street's influential donors are resigned to watching and waiting as the Democratic Party faces a major crisis. While some believe that a change at the top of the ticket would boost the Democrats' chances of beating Trump, there is no obvious path for these donors to make that change happen themselves. Efforts to drum up funds for an alternative candidate have fallen short, and Biden's political operation has $240 million on hand. Some wealthy donors have said they will withhold future contributions until Biden is off the ticket, and there are concerns that Democratic congressional candidates will lose to Republicans with Biden as the nominee. However, Biden remains committed to staying in the race and beating Trump, and the campaign is reaching out to wealthy donors for support. [Extracted from the article]

Published
2024

Catalog

Books, media, physical & digital resources
See catalog results